Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer-Reference-Cited by-同舟云学术

Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer

Published:2016-08-12 Issue:9 Volume:107 Page:1315-1320
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kokuryo Toshio¹²,Hibino Shigeru¹²,Suzuki Kazushi¹²,Watanabe Katsutaka¹,Yokoyama Yukihiro¹,Nagino Masato¹,Senga Takeshi²,Hamaguchi Michinari²

Affiliation:

1. Division of Surgical Oncology Nagoya University Graduate School of Medicine Nagoya Japan

2. Division of Cancer Biology Nagoya University Graduate School of Medicine Nagoya Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12993

Reference22 articles.

1. Systemic Chemotherapy for Pancreatic Cancer

2. Treatment of Pancreatic Cancer: Challenge of the Facts

3. Cell cycle‐dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans;Schultz SJ;Cell Growth Differ,1994

4. Never say never. The NIMA-related protein kinases in mitotic control

5. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA nanomedicine in liver diseases;Hepatology;2023-09-19

2. Identification of Key Regulators in Pancreatic Ductal Adenocarcinoma Based on Integrated Analysis of Experimental Data and Bioinformatics;J BIOL REG HOMEOS AG;2023

3. Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer;Anticancer Research;2023-02-28

4. Bio-assembled smart nanocapsules for targeted delivery of KRAS shRNA and cancer cell bioimage;Chinese Chemical Letters;2023-01

5. Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment;Journal of Clinical Pharmacy and Therapeutics;2022-09-10